The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Rituximab-related viral infections in lymphoma patients
Abstract
Recently, a human/mouse chimeric monoclonal antibody, rituximab, has been successfully used to treat cases of B-cell non-Hodgkin's lymphoma and some autoimmune diseases. However, several viral infections related to rituximab have been reported in the literature, but were not well characterized. To further investigate this topic, relevant English language studies were identified through Medline. There were 64 previously reported cases of serious viral infection after rituximab treatment. The median age of the cases was 61 years (range: 21 - 79). The median time period from the start of rituximab treatment to viral infection diagnosis was 5.0 months (range: 1 - 20). The most frequently experienced viral infections were hepatitis B virus (HBV) (39.1%, n = 25), cytomegalovirus infection (CMV) (23.4%, n = 15), varicella-zoster virus (VZV) (9.4%, n = 6), and others (28.1%, n = 18). Of the patients with HBV infections, 13 (52.0%) died due to hepatic failure. Among the 39 cases that had viral infections other than HBV, 13 died due to these specific infections. In this study, about 50% of the rituximab-related HBV infections resulted in death, whereas this was the case in only 33% of the cases with other infections. Close monitoring for viral infection, particularly HBV and CMV, in patients treated with rituximab should be recommended.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
TROTTI, A., COLEVAS, A., SETSER, A., RUSCH, V, JAQUES, D., BUDACH, V, LANGER, C., MURPHY, B., CUMBERLIN, R., & COLEMAN, C. (2003) · Seminars in Radiation Oncology · doi:10.1016/s1053-4296(03)00031-6 · Cited by 2,569
Czuczman, M. S., Grillo-López, A. J., White, C. A., Saleh, M., Gordon, L., LoBuglio, A. F., Jonas, C., Klippenstein, D., Dallaire, B., & Varns, C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.268 · Cited by 856
Byrd, J. C. (2003) · Blood · doi:10.1182/blood-2002-04-1258 · Cited by 571
Thomas, D. A., Faderl, S., O'Brien, S., Bueso‐Ramos, C., Cortes, J., Garcia‐Manero, G., Giles, F. J., Verstovsek, S., Wierda, W. G., Pierce, S. A., et al. (2006) · Cancer · doi:10.1002/cncr.21776 · Cited by 566
Tolerability and safety of rituximab (MabThera®)
Kimby, E. (2005) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2005.05.007 · Cited by 470
Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon α with an anti-CD20
Sansonno, D., De Re, V., Lauletta, G., Tucci, F. A., Boiocchi, M., & Dammacco, F. (2003) · Blood · doi:10.1182/blood-2002-10-3162 · Cited by 370
Yeo, W., Zee, B., Zhong, S., Chan, P. K. S., Wong, W.-L., Ho, W. M., Lam, K. C., & Johnson, P. J. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601699 · Cited by 312
Infectious and immunosuppressive complications of purine analog therapy.
Cheson, B. D. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.9.2431 · Cited by 260
Cited by
Carson, K. R., Evens, A. M., Richey, E. A., Habermann, T. M., Focosi, D., Seymour, J. F., Laubach, J., Bawn, S. D., Gordon, L. I., Winter, J. N., et al. (2009) · Blood · doi:10.1182/blood-2008-10-186999 · Cited by 866
The immunology of multiple sclerosis
Attfield, K. E., Jensen, L. T., Kaufmann, M., Friese, M. A., & Fugger, L. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00718-z · Cited by 380
Chellapandian, D., Das, R., Zelley, K., Wiener, S. J., Zhao, H., Teachey, D. T., Nichols, K. E., & EBV‐HLH Rituximab Study Group (2013) · British Journal of Haematology · doi:10.1111/bjh.12386 · Cited by 251
“Other rare yet significant side effects of rituximab include development of thrombocytopenia, neutropenia and anaemia (Kimby, 2005; Wolach et al, 2010), and reactivation of specific viral infections (Aksoy et al, 2007).”
Background
Metadata
- Authors
- Aksoy, S., Harputluoglu, H., Kilickap, S., Dede, D. S., Dizdar, O., Altundag, K., & Barista, I.
- Venue
- Leukemia & Lymphoma
- Publisher
- Informa UK Limited
- Published
- 2007-01
- Volume
- 48
- Issue
- 7
- Pages
- 1307-1312
- ISSN
- 1026-8022 (ISSN-L)
- 1042-8194
- 1029-2403
- OpenAlex
- W1994630947
- Cited by
- 253
- References
- 26
- FWCI
- 9.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rituximab-related viral infections in lymphoma patients. https://app.cochat.ai/papers/10.1080/10428190701411441
- The paper
- Aksoy, S., Harputluoglu, H., Kilickap, S., Dede, D. S., Dizdar, O., Altundag, K., & Barista, I. (2007). Rituximab-related viral infections in lymphoma patients. Leukemia & Lymphoma. https://doi.org/10.1080/10428190701411441
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
